Chrystal Louis

TScan Therapeutics has cut approximately three-quarters of its workforce, paused further enrolment in its Phase 3 ALLOHA-2 trial and removed both its chief financial officer and chief medical officer as it redirects its remaining capital toward in vivo cell therapy.